Unveiling 15 Analyst Insights On Sarepta Therapeutics | Nasdaq

Oct 21, 2024 · 15 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) ... Unveiling 15 Analyst Insights On Sarepta Therapeutics October 21, 2024 …

$188.31
OFF

Unveiling 26 Analyst Insights On Sarepta Therapeutics | Nasdaq

2 weeks from now

Sep 6, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $188.31, a high estimate of $235.00, and a low estimate of $128.00.

nasdaq.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

$157.21
OFF

What Analysts Are Saying About Sarepta Therapeutics Stock

2 weeks from now

May 2, 2024 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $157.21, with a high estimate of $224.00 and a low estimate of $128.00.

businessinsider.com

$157.23
OFF

In-Depth Examination Of 13 Analyst Recommendations For …

2 weeks from now

Feb 15, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $157.23, a high estimate of $224.00, and a low …

businessinsider.com

$168.79
OFF

Analyst Expectations For Sarepta Therapeutics's Future

2 weeks from now

Nov 25, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00.

benzinga.com

$177.25
OFF

Peeling Back The Layers: Exploring Sarepta Therapeutics ... - Nasdaq

2 weeks from now

Oct 21, 2024 · The 12-month price targets, analyzed by analysts, offer insights with an average target of $177.25, a high estimate of $205.00, and a low estimate of $150.00.

nasdaq.com

$182
OFF

Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25

2 weeks from now

Jul 1, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $182.8, a high estimate of $235.00, and a low …

nasdaq.com

$185
OFF

A Closer Look At 28 Analyst Recommendations For Sarepta

2 weeks from now

Aug 15, 2024 · Sarepta Therapeutics (NASDAQ:SRPT) ... offer insights with an average target of $185.0, a high estimate of $235.00, and a low estimate of $128.00. ... Stay up to date on …

nasdaq.com

$336
OFF

What 15 Analyst Ratings Have To Say About Alnylam …

2 weeks from now

2 days ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.2, a high estimate of $400.00, and a low estimate of $296.00.

nasdaq.com

$16.83
OFF

A Glimpse Into The Expert Outlook On Amicus Therapeutics

2 weeks from now

2 days ago · Analysts have set 12-month price targets for Amicus Therapeutics, revealing an average target of $16.83, a high estimate of $21.00, and a low estimate of $12.00.

nasdaq.com

FAQs about Unveiling 15 Analyst Insights On Sarepta Therapeutics | Nasdaq Coupon?

What is the average price target for Sarepta Therapeutics?

In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $157.23, a high estimate of $224.00, and a low estimate of $109.00. Witnessing a positive shift, the current average has risen by 24.79% from the previous average price target of $126.00. ...

How do analysts evaluate Sarepta Therapeutics?

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. ...

Why do analysts'maintain' or 'raise' their stance on Sarepta Therapeutics?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. ...

What does a Sarepta Therapeutics rating mean?

Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market. ...

Should you buy Sarepta Therapeutics (SRPT) stock?

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating on January 8. Anupam Rama has given his Buy rating due to a combination of factors highlighting the promising outlook for Sarepta Therapeutics. ...

Does Sarepta Therapeutics have a high debt-to-equity ratio?

Debt Management: With a high debt-to-equity ratio of 1.63, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. ...